The ARB/PPAR-γ partial agonist telmisartan significantly decreases hypertension and fibrocystic liver disease in association with inhibition of the TGF-β signaling pathways in PCK rats, an orthologous model of human ARPKD. The gene discussed is PPARG; the disease is autosomal recessive polycystic kidney disease.